Toshiharu Morikawa

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Combination Therapy

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Radical Prostatectomy

Top Venues

IJU case reports

Journal of clinical medicine

Diagnostics (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Toshiharu Morikawa, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Keitaro Iida, Teruki Isobe, Yusuke Noda, Nobuhiko Shimizu, Maria Aoki, Masakazu Gonda, Rika Banno, Hiroki Kubota, Ryosuke Ando, Yukihiro Umemoto, Noriyasu Kawai, Takahiro Yasui
C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study. Cancers 16 (9) (2024)
Shuzo Hamamoto, Yoshihiko Tasaki, Toshiharu Morikawa, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Shoichiro Iwatsuki, Rei Unno, Tomoki Takeda, Takashi Nagai, Kengo Kawase, Yoshihisa Mimura, Yosuke Sugiyama, Atsushi Okada, Yoko Furukawa-Hibi, Takahiro Yasui
Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma. Journal of clinical medicine 13 (12) (2024)
Shuzo Hamamoto, Yoshihiko Tasaki, Toshiharu Morikawa, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Shoichiro Iwatsuki, Rei Unno, Tomoki Takeda, Takashi Nagai, Kengo Kawase, Yoshihisa Mimura, Yosuke Sugiyama, Atsushi Okada, Yoko Furukawa-Hibi, Takahiro Yasui
Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma. Journal of clinical medicine 13 (12) (2024)
Toshiharu Morikawa, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Keitaro Iida, Teruki Isobe, Yusuke Noda, Nobuhiko Shimizu, Maria Aoki, Masakazu Gonda, Rika Banno, Hiroki Kubota, Ryosuke Ando, Yukihiro Umemoto, Noriyasu Kawai, Takahiro Yasui
C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study. Cancers 16 (9) (2024)
Toshiharu Morikawa, Shoichiro Iwatsuki, Aya Naiki-Ito, Masakazu Gonda, Kazumi Taguchi, Taku Naiki, Shuzo Hamamoto, Atsushi Okada, Takahiro Yasui
Urothelial carcinoma occurring in a defunctionalized bladder after urinary diversion due to the bladder exstrophy-epispadias complex. IJU case reports 7 (2) (2023)
Maria Aoki, Taku Naiki, Aya Naiki-Ito, Toshiharu Morikawa, Nayuka Matsuyama, Koei Torii, Taiki Kato, Tetsuji Maruyama, Shingo Inaguma, Takahiro Yasui
Successful treatment with enfortumab-vedotin of metastatic signet ring cell cancer expressing nectin-4 and originating from the bladder. IJU case reports 7 (2) (2023)
Toshiharu Morikawa, Shoichiro Iwatsuki, Aya Naiki-Ito, Masakazu Gonda, Kazumi Taguchi, Taku Naiki, Shuzo Hamamoto, Atsushi Okada, Takahiro Yasui
Urothelial carcinoma occurring in a defunctionalized bladder after urinary diversion due to the bladder exstrophy-epispadias complex. IJU case reports 7 (2) (2023)
Maria Aoki, Taku Naiki, Aya Naiki-Ito, Toshiharu Morikawa, Nayuka Matsuyama, Koei Torii, Taiki Kato, Tetsuji Maruyama, Shingo Inaguma, Takahiro Yasui
Successful treatment with enfortumab-vedotin of metastatic signet ring cell cancer expressing nectin-4 and originating from the bladder. IJU case reports 7 (2) (2023)
Nayuka Matsuyama, Taku Naiki, Shuzo Hamamoto, Yosuke Sugiyama, Yasue Kubota, Takashi Hamakawa, Toshiki Etani, Shoichiro Iwatsuki, Kazumi Taguchi, Yuya Ota, Masakazu Gonda, Maria Aoki, Toshiharu Morikawa, Taiki Kato, Atsushi Okada, Takahiro Yasui
Postoperative Bladder Neck to Pubic Symphysis Ratio Predictive for De Novo Overactive Bladder after Robot-Assisted Radical Prostatectomy. Diagnostics (Basel, Switzerland) 13 (20) (2023)